C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 5.68 USD -4.86% Market Closed
Updated: May 18, 2024

C4 Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

C4 Therapeutics Inc
Total Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C4 Therapeutics Inc
NASDAQ:CCCC
Total Equity
$246.1m
CAGR 3-Years
-4%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Equity
$8B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$17.5B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$5B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-14%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$18.5B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$27B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
28%

See Also

What is C4 Therapeutics Inc's Total Equity?
Total Equity
246.1m USD

Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Total Equity amounts to 246.1m USD.

What is C4 Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 5Y
51%

Over the last year, the Total Equity growth was -15%. The average annual Total Equity growth rates for C4 Therapeutics Inc have been -4% over the past three years , 51% over the past five years .